IOVANCE BIOTHERAPEUTICS, INC.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp disclosed a stake exceeding 5% in Iovance Biotherapeutics Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000677). The filing signals that the institutional investor has crossed the 5% beneficial ownership threshold, making it a notable holder in the clinical-stage biotech. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify the size and nature of the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Iovance Biotherapeutics, Inc.